Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
Submitting Your Manuscript
AIDS Research and Human Retroviruses welcomes format-neutral manuscripts for first-time submissions. Newly submitted manuscripts will not be un-submitted for formatting issues. However, after the initial peer review process, revised submissions must follow correct journal formatting and file guidelines, as described below in the Instructions for Authors. Please note that there are certain compulsory elements (ie: IRB approvals, author disclosures, etc.) for all new submissions. Manuscripts submitted without this information will be un-submitted and the submitting author will be asked to add the required components.
All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.
Manuscript Submission Site
All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.
All Original submissions must contain:
- An Internal Review Board (IRB) approval (or waiver) statement in the Methods section
- Acknowledgments section (if applicable) after the Conclusion of the paper, followed by
- Sequence Data / Accession Number(s) (if applilcable) followed by
- An Author Contribution statement for each listed author, followed by
- An Author Disclosure Statement for each author listed on a submission, even if there are no conflicts to disclose, followed by,
- Funding statement(s), even if there is no funding information to declare.
AIDS Research and Human Retroviruses has adopted the recommendations of the Executive Committee of the International Committee on Taxonomy of Viruses (ICTV) (Ref: Science 232:1486, 1986, and Nature 321:644, 1986) to designate viruses associated with AIDS. The Committee’s suggestion was to use HIV (human immunodeficiency virus) or the generic name for this class of human retroviruses. The Committee also recommended maintaining the specific strain names (LAV-1BRU, LAV-1LOI, HTLV-IIIB, HTLV-IIIRF, ARV1 . . .) in the interest of continuity and appreciation for the biologic and molecular differences of the individual strains. Thus, for the sake of accuracy, the editors encourage the use of specific strain names in experimental details.
AIDS Research and Human Retroviruses requires submission of accession numbers with any manuscript that uses sequence data. The numbers must be listed in a separate section following Acknowledgments section. Accession numbers can be obtained from Genbank, EMBL, or DDBJ.
When submitting your manuscript for peer review, be prepared to :
- Enter the full title of the manuscript
- Enter the full names and institutional affiliations of ALL listed authors
- Enter ALL listed authors' institutional email addresses
- Identify the corresponding author
- Enter a running (abbreviated) title of no more than 50 characters (including spaces).
- Enter 3–5 keywords or phrases.
- Provide a structured abstract of no more than 250 words, stating the background, methods, and results (including the sample size), drawn from the study.
- Provide the names and email addresses of at least five potential preferred reviewers familiar with the field. Please make sure preferred reviewers are not from your university or institution or with whom you have collaborated. Anyone whom the author does not want to be considered should also be named as a non-preferred reviewer. Ultimate reviewer selection is at the Editor’s discretion.
- Confirm that the material has not been published or submitted for publication elsewhere.
All file names should be in English and contain only alphanumeric charachters. Do not include spaces, sybmols, special characters, dashes, dots, or underscores. Label each file with the first author's last name, followed by the content of the file (ie: SmithText; SmithTables; SmithFigureLegends; SmithFig1, etc)
Important: Please upload individual files of all manuscript material as described herein — please do NOT upload a combined PDF file containing all material in your submission.
Preparation of Manuscript
Prepare text of manuscripts, figure legends, and tables in Microsoft Word, double spaced. The order of elements in each manuscript should be:
- Title page (with full manuscript title, all contributing authors and their affiliations, a short running title, a denotation of the corresponding author, and a list of 3-6 keywords
- Main text (do not embed figures or tables)
- Conclusion (as a separate paragraph, not as part of the Discussion section)
- Acknowledgments (if applicable)
- Sequence Data / Accession Number(s)
- Authorship confirmation statement (see below)
- Author(s’) disclosure statement(s) (see below)
- Funding statement (see below)
- Figure legends
- Supplemental files (if applicable. If the submission is accepted, Supplemental Information will NOT be published in the Just Accepted/LION platform, but instead will be published in the Online Now (epub) and final versions of the article. Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)
Maximum word count should not exceed 4,000 words. In general, the text should be organized under the headings: Introduction, Materials and Methods, Results, Discussion, and Conclusions. Use only standard abbreviations, which can be found in the AMA’s Manual for Authors & Editors or the Council of Biology Editors Style Manual, 10/e. At first usage, spell out terms and provide abbreviations in parentheses. Thereafter, use only the abbreviations. It is not necessary to spell out standard units of measure. Use generic names for drugs if possible. If you wish to use a proprietary drug name the first time it appears, use the generic name followed by the proprietary name, manufacturer, and location in parentheses.
References must be prepared in word, double spaced, and numbered consecutively as they are cited in the text (using superscript numbers). Include reference section as part of the main text file, not as aseparate file. References appearing for the first time in tables and figures must be numbered in sequence with those cited in the text where the table or figure is mentioned. Use journal abbreviations as provided by PubMed/Medline. List all authors when there are six or less. When there are more than six, list the first three, followed by et al. If references to personal communications or unpublished data are used, they are not to be in the list of references. They should be referred to in the text in parentheses: (AB Jones, personal communication). Include among the references any papers that have been accepted but have not yet published; identify the name of publication and add "In Press." If the reference has been published online, provide the DOI number in place of the page range.
Sample style for references:
- Journal article:
Hendrix CW,Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses 2015;32(1):32-43.
Vicenzi E, Poli G. Human Retroviruses: Methods and Protocols (Methods in Molecular Biology). Totowa, NJ: Human Press (Springer) 2014.
- Chapter in a book:
Cimarelli A, Darlix J-L. HIV-1 Reverse transcription. In: Human Retroviruses: Methods and Protocols (Methods in Molecular Biology), (Vicenzi E, Poli G.,eds.) Totowa, NJ: Human Press (Springer) 2014; pp. 55-70.
Figure legends should be uploaded as a separate Word file and double spaced. In the legend, provide explanations for any abbreviations, arrows, etc. that appear in the figure. If the illustration is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.
All tables should be prepared in one single Word file. Provide a title for each table. Cite tables in sequence in the text. Explain abbreviations used in the body of the table in footnotes. If the table is taken from a copyrighted publication, permission must be secured, appropriate credit must be given in the legend, and a corresponding reference must appear in the reference section.
- Submission of high resolution .TIFF or .EPS figure files is strongly recommended.
- Figures should not be embedded within the manuscript file.
- Cite figures consecutively in text within parentheses.
- A legend should be supplied for each figure and all legends numbered consecutively.
- Images should not show the name of a patient or a manufacturer.
- Do not include any illustrations as part of your text file.
Following the references, provide the name and complete affiliation and eamil address of the person to whom correspondence should be sent.
To upload a revision of a paper, the submitting author should log in to their Author Center at http://mc.manuscriptcentral.com/aidsresearch and click on “Revised Manuscripts in Draft.” All revised submissions will be required to meet all formatting conditions described herein. Submissions that do not satisfy these requirements will be un-submitted and returned to the submitting author for proper configuration.
Letters to the Editor
AIDS Research and Human Retroviruses will consider Letters to the Editor commenting on the scientific content of an article published in the Journal. Letters should not exceed 400-500 words of text and 5 references. Letters submitted for publication must be original and must not be submitted to any other publication simultaneousl
Journal Policies on:
Licensing Information: OPEN ACCESS and Copyright
Data Sharing and Preprint Policies
Post-Acceptance and Post-Publication Policies
Correction Statements / Retractions
Reprints, Permissions, & Social Media Use
Plagiarism Detection Software
Definitions of Scientific Misconduct
Responding to Allegations of Scientific Misconduct
Press Embargo Policy
Archiving and Preservation
For questions regarding manuscript submissions, contact our Author Services Division.
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email email@example.com.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email firstname.lastname@example.org or visit Liebert Open Access for more information.